Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 159 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug Toxicity Clear all
Withdrawn Not applicable Interventional

Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study

NCT02795143
View directory record Official record
Conditions
Toxic Epidermal Necrolysis
Interventions
Isotretinoin, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 1 Interventional

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

NCT00002818
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
cytarabine, deoxycytidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional Results available

Regional Data Exchange to Improve Medication Safety

NCT01239121
View directory record Official record
Conditions
Drug Toxicity
Interventions
HIE-Enhanced Medication Reconciliation, Optimal Medication Reconciliation without HIE
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2016 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors

NCT00003811
View directory record Official record
Conditions
Childhood Germ Cell Tumor, Drug/Agent Toxicity by Tissue/Organ, Extragonadal Germ Cell Tumor, Ovarian Cancer
Interventions
bleomycin sulfate, amifostine trihydrate, cisplatin, etoposide, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 14 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Jul 21, 2026, 11:10 AM EDT
Completed No phase listed Observational

SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial

NCT00002900
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
management of therapy complications
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
105
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 3 Interventional

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

NCT00075868
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ, Radiation Enteritis
Interventions
octreotide acetate, Placebo
Drug · Other
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
112
States / cities
Mobile, Alabama • Phoenix, Arizona • Chico, California + 89 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Jul 21, 2026, 11:10 AM EDT
Completed No phase listed Observational

Evaluation of MyoStrain™ in Clinical Practice

NCT03825224
View directory record Official record
Conditions
Cardiac Failure, Coronary Artery Disease, Sarcoidosis, Amyloidosis, Lupus, Myocarditis, Drug Toxicity
Interventions
Diagnostic Test: Myostrain
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Not listed
Enrollment
19 participants
Timeline
2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 1 Interventional

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

NCT00093353
View directory record Official record
Conditions
Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma
Interventions
cefixime, irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Early Phase 1 Interventional

AvenovaTM as a Sterile Skin Preparation Agent

NCT02990013
View directory record Official record
Conditions
Cleaning Product Causing Toxic Effect
Interventions
Avenova, Povidone-iodine 5% solution, 4% chlorhexidine, Isopropyl alcohol
Device · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 21, 2026, 11:10 AM EDT
Terminated Phase 4 Interventional Results available

L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer

NCT00754767
View directory record Official record
Conditions
Breast Cancer, Chemotherapeutic Agent Toxicity, Neurotoxicity
Interventions
L-carnitine L-tartrate, placebo
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Jul 21, 2026, 11:10 AM EDT
Recruiting Not applicable Interventional

Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy

NCT07073807
View directory record Official record
Conditions
Cancer, Neoplasms
Interventions
SMART Intervention using TAPPT® for Adherence, Symptom, Financial, and Social Needs Monitoring
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Irvine, California • Newport Beach, California • Orange, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Withdrawn Phase 2 Interventional

Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML

NCT00003407
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes, Neutropenia
Interventions
amifostine trihydrate, cytarabine, mitoxantrone hydrochloride
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
4
States / cities
Chicago, Illinois • Kankakee, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 1 Interventional

Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

NCT00003144
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
amifostine trihydrate, cisplatin, gemcitabine hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2011 · Synced Jul 21, 2026, 11:10 AM EDT
Not listed No phase listed Observational

Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs

NCT01208545
View directory record Official record
Conditions
Chemotherapy, Nerve Degeneration, Nerve Conduction
Interventions
Not listed
Lead sponsor
NeuroMetrix, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2010 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional Results available

Switching to Potential Reduced Exposure Products in Adult Smokers

NCT04250727
View directory record Official record
Conditions
Tobacco Use Disorder, Oral Nicotine Pouch Use, Smoking Behaviors, Harm Reduction, Toxic Effect of Tobacco and Nicotine, Carcinogenesis
Interventions
ZYN
Device
Lead sponsor
Yale University
Other
Eligibility
21 Years to 77 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Jul 21, 2026, 11:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Comparison of Infection Rates Between Two Surgical Sites

NCT01263262
View directory record Official record
Conditions
Corneal Toxicity, Ototoxicity, Surgical Site Infection
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Jul 21, 2026, 11:10 AM EDT
Not listed Phase 2 Interventional

Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer

NCT00003583
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
Interventions
amifostine trihydrate, cisplatin, etoposide, radiation therapy
Drug · Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 2 Interventional

Randomized Amifostine For SCCHN

NCT00095927
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Head and Neck Cancer, Mucositis, Radiation Toxicity, Xerostomia
Interventions
Amifostine, Carboplatin, Paclitaxel, radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
9
States / cities
Sanford, Maine • Boston, Massachusetts • Concord, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

MW151-101: First-in-human Study of MW151

NCT04120233
View directory record Official record
Conditions
Drug Toxicity
Interventions
Placebo, MW151, 10mg, MW151, 20mg, MW151, 40mg, MW151, 80mg, MW151, 160mg
Drug
Lead sponsor
Linda Van Eldik
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Jul 21, 2026, 11:10 AM EDT
Recruiting Early Phase 1 Interventional

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

NCT05530655
View directory record Official record
Conditions
Prostate Cancer, Radiation Toxicity, Urinary Complication
Interventions
Lisinopril Tablets
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 2 Interventional Results available

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

NCT01009918
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
Coreg CR®, lisinopril, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
174
States / cities
Long Beach, California • Sylmar, California • Aurora, Colorado + 142 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aminotransferase Trends During Prolonged Acetaminophen Dosing

NCT00743093
View directory record Official record
Conditions
Drug Toxicity, Healthy
Interventions
acetaminophen, placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

NCT01135680
View directory record Official record
Conditions
Drug Toxicity
Interventions
HPN-100, HPN-100 or Placebo, Placebo, Moxifloxacin
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 3 Interventional Results available

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

NCT00400946
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Interventions
asparaginase, cyclophosphamide, cytarabine, dexamethasone, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, leucovorin calcium, mercaptopurine, methotrexate, methylprednisolone, pegaspargase, prednisolone, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 21, 2026, 11:10 AM EDT